Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Stock Information for OptiNose Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OptiNose Inc.

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Optinose to Present at the Needham Virtual Healthcare Conference
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.